FDA May Need To Reduce Timeframe For Inspecting Flu Vaccine Facilities, Rep. Davis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
House Government Reform Committee Chairman Tom Davis (R-Va.) indicated interest in revising FDA's procedures regarding inspection of flu vaccine manufacturing facilities in light of the current supply shortage
You may also be interested in...
Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
Rep. Waxman To FDA: Rely On Inspectors, Not Industry, For Compliance
FDA should rely more on the recommendations of its inspectors and less on regulated industry to ensure compliance, Rep. Henry Waxman (D-Calif.) said
Rep. Waxman To FDA: Rely On Inspectors, Not Industry, For Compliance
FDA should rely more on the recommendations of its inspectors and less on regulated industry to ensure compliance, Rep. Henry Waxman (D-Calif.) said